– USA, MA – Orogen Therapeutics, Inc., a drug discovery company, announced the additions of Dr. Mikael Dolsten (M.D., Ph.D.) and Dieter Weinand to its Board as Independent Non-Executive Directors. Dr. Dolsten will also serve as Chairman of the Board.
About Mikael Dolsten, M.D., Ph.D.
Dr. Mikael Dolsten serves as Chairman of the Orogen Board. During his 16-year tenure as CSO and President of Research and Development at Pfizer, he oversaw the regulatory approval of over 36 medicines and vaccines, while advancing more than 150 drug candidates into clinical studies. He championed breakthrough innovations across small-molecule medicines, biotherapeutics, gene therapies, and vaccines, and played a leading role in the global response to the COVID pandemic.
His leadership experience includes serving as President of Wyeth Research, EVP and Head of Worldwide Research at Boehringer Ingelheim, and Global VP at AstraZeneca, managing cardiovascular, metabolic, and gastrointestinal R&D. Earlier, he led R&D at Astra Draco (pulmonary & inflammation) and headed Immunology-Oncology research at Pharmacia. During his 30+ years as an R&D leader, he has been connected to some 50 drug and vaccine approvals and several hundred novel candidate drugs transiting to clinical studies. Dr Dolsten has VC experience from work with Orbimed, ATP, nd Pfizer venture groups. He has, in his Pharma career, been involved in numerous small and large corporate transactions exceeding $100B in the aggregate. He currently sits on the public boards of Agilent Technologies and Rocket Pharmaceuticals, serves several private biotechs including Orbis Medicine, Fair Journey Biologics, ImmuneAi, Quarry Thera and ChAI discovery, is a senior advisor to Blackstone Life Sciences and GV (Google Ventures), is affiliated with the Scripps Research Institute and the Foundation for the National Institutes of Health (NIH), and is a member in The Royal Swedish Academy of Engineering Sciences. From 2014-24, Mikael co-chaired the Accelerating Medicine Partnership with NIH. He also served on the PhRMA Research & Development Leadership Forum and the PhRMA Foundation board of directors. Dr Dolsten has advised the Obama, Trump, and Biden administrations in public health initiatives and the UK G7 leadership for pandemic responses.
With over 160 scientific publications and numerous patents, Dr. Dolsten holds a Ph.D. in Tumor Immunology and an M.D. from the University of Lund, Sweden, where he serves as a Visiting Professor.
About Dieter Wienand
Dieter Weinand is an experienced business leader with over 30 years of experience in the pharmaceutical industry and is the former CEO and Chairman of the board of Bayer Pharmaceuticals AG. He earned an M.S. in pharmacology and toxicology from Long Island University, New York, and a B.A. in biology from Concordia College, New York. During a career stretching back over 30 years, he has held various responsibilities in general management, commercial, operational and strategic leadership roles, leading business operations in the Asia-Pacific region, Europe, the Middle East, Africa, Latin America and the United States, for companies including Bayer, Pfizer, Bristol-Myers Squibb, and Sanofi. He has also led the launch and marketing of products in various therapeutic areas, including cardiovascular diseases, oncology, dermatology, immunology, respiratory diseases, and inflammatory diseases. He is the former Chairman of the Board and current lead independent director of Replimune (REPL), Chairman of the Board of Clasp Tx, Executive Chairman of the Board of Fore Bio, and a member of the board of directors of Coya (COYA).
About Orogen Therapeutics
Orogen Therapeutics’ mission is to deliver groundbreaking clinical solutions to patients with serious unmet medical needs. The company is revolutionizing small-molecule drug discovery through its proprietary platform, integrating DNA-encoded libraries (DEL) with massive chemical diversity of billions of compounds, virtual screening, and AI-driven computation. The company’s proprietary, one-of-a-kind target-specific FocusDEL (patent pending) seeks to innovate the DEL landscape by enabling enriched hit yields from immense chemical spaces. This unique foundation is designed to enable the efficient derivation of novel drug candidates against a broad range of target classes.
Orogen’s team includes scientists with decades of drug development experience and deep expertise in all aspects of small-molecule R&D, including DNA-encoded libraries, target selection and evaluation, cutting-edge AI, and data science.
Orogen applies its DEL- and AI-enabled platform to specific targets, therapeutic areas, and clinical indication verticals, the first of which is developing small-molecule alternatives to biological products in the immuno-inflammation (INI) space. Early screening successes yielded hit series against multiple cytokine targets, with several candidates in lead optimization moving toward anticipated near-term lead selection. Medically and commercially successful biologics developed for cytokine targets have highlighted the value of this space in multiple therapeutic areas, including dermatology, rheumatology, and gastroenterology, for indications like psoriasis, eczema, psoriatic arthritis, rheumatoid arthritis, Crohn’s disease, and IBD. Oral small-molecule medicines with good safety and efficacy profiles may represent attractive alternatives to biologics.
For more information: https://orogentx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.